Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P.

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

Sana Biotechnology (SANA) and eBay (EBAY) are two of the stocks rallying this morning despite the market’s losses. Sana is ...

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Sana Biotechnology (SANA – Research Report) and keeping the price target ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -68.45%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...